200953-44-2

Upstream product

• 200953-43-1 (5R,6S)-3-(2-Methoxy-phenyl)-6-phenyl-1-oxa-7-aza-spiro[4.5]dec-3-ene-7-carboxylic acid tert-butyl ester 
• 159249-47-5 tert-butyl (2S,3S)-3-hydroxy-2-phenylpiperidine-1-carboxylate 
• 148701-46-6 cis-(3S)-hydroxy-(2S)-phenylpiperidine 
• 191669-62-2 (S)-tert-butyl 3-carbonyl-2-phenylpiperidine-1-carboxylic acid 
• 200956-07-6 (5R,6S)-3-Oxo-6-phenyl-1-oxa-7-aza-spiro[4.5]decane-7-carboxylic acid tert-butyl ester 
• 200956-06-5 (5R,6S)-3-Methylene-6-phenyl-1-oxa-7-aza-spiro[4.5]decane-7-carboxylic acid tert-butyl ester 
• 200956-05-4 (2S,3R)-1-tert-butoxycarbonyl-3-hydroxy-3-(2-methylene-3-phenoxypropyl)-2-phenylpiperidine 
• 200956-08-7 (5R,6S)-6-Phenyl-3-trifluoromethanesulfonyloxy-1-oxa-7-aza-spiro[4.5]dec-3-ene-7-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Spirocyclic NK1 antagonists II: [4.5]-spiroethers

A series of novel spiroether-based neurokinin-1 (NK1) antagonists is described. The effect of modifications to the spiroether ring and aromatic substituents are discussed, leading to the identification of compounds with high affinity and excellent CNS penetration.